Cellectis S.A. (CLLS) vs NeOnc Technologies (NTHI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
NeOnc Technologies (NTHI) has outperformed Cellectis S.A. (CLLS) over the past year, losing 46.2% versus a loss of 80.4%. Cellectis S.A. is the larger company by market cap ($92.8 million vs $90.9 million), about 1.0 times the size. Cellectis S.A. converts more of its revenue into profit, with a net margin of -92.7% versus -155404.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLLS | NTHI |
|---|---|---|
| Share price | $0.9209 | $3.15 |
| Market cap | $92.76M | $90.88M |
| 1-day change | -7.89% | -9.48% |
| YTD return | -80.97% | -61.91% |
| 1-year return | -80.36% | -46.25% |
| 5-year return | -89.40% | — |
| EPS (TTM) | $-1.26 | $-1.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $72.95M | $39.99K |
| Revenue growth (YoY) | +75.76% | -51.82% |
| Net income (latest FY) | $-67.59M | $-62.15M |
| Gross margin | 100.00% | — |
| Operating margin | -45.34% | -145637.52% |
| Net margin | -92.66% | -155404.38% |
| 52-week high | $5.45 | $11.38 |
| 52-week low | $0.881 | $2.50 |
| Distance from 52-week high | -83.10% | -72.31% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +497.24% | +439.68% |
| Average volume | 115.00K | 187.23K |
| Shares outstanding | 72.73M | 28.85M |
| Employees | 224 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NTHI has outperformed CLLS by 34.1 percentage points over the past year.
- Cellectis S.A. is more profitable, keeping -92.7 cents of every revenue dollar as net income versus -155404.4 cents for NeOnc Technologies.
- Cellectis S.A. grew revenue faster in its latest fiscal year (+75.76% vs -51.82%).
About Cellectis S.A.
CLLS stock →Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
Health Care · Biotechnology: Pharmaceutical Preparations · 224 employees
About NeOnc Technologies
NTHI stock →NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
CLLS vs NTHI FAQ
Which is bigger, Cellectis S.A. or NeOnc Technologies?
Cellectis S.A. (CLLS) is larger, with a market capitalization of $92.76M compared with $90.88M for NeOnc Technologies (NTHI).
Which stock has performed better over the past year, CLLS or NTHI?
NTHI returned -46.25% over the past 12 months, compared with -80.36% for CLLS (price return, excluding dividends). Past performance does not predict future results.
Are Cellectis S.A. and NeOnc Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.